Infinity Pharmaceuticals (NASDAQ:INFI) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03, Fidelity Earnings reports. The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.05 million.

Shares of Infinity Pharmaceuticals stock traded down $0.02 during trading on Friday, reaching $1.89. The company had a trading volume of 186,287 shares, compared to its average volume of 231,660. The firm has a market cap of $81.89 million, a PE ratio of -2.28 and a beta of 2.17. Infinity Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $2.92.

Several large investors have recently made changes to their positions in INFI. Fosun International Ltd bought a new stake in shares of Infinity Pharmaceuticals during the 3rd quarter valued at about $879,000. Dimensional Fund Advisors LP grew its position in shares of Infinity Pharmaceuticals by 14.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,065,874 shares of the biotechnology company’s stock valued at $2,889,000 after buying an additional 133,504 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Infinity Pharmaceuticals by 35.7% during the 3rd quarter. Renaissance Technologies LLC now owns 736,700 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 194,000 shares during the last quarter. EcoR1 Capital LLC grew its position in shares of Infinity Pharmaceuticals by 12.2% during the 3rd quarter. EcoR1 Capital LLC now owns 462,068 shares of the biotechnology company’s stock valued at $1,252,000 after buying an additional 50,068 shares during the last quarter. Finally, Opaleye Management Inc. bought a new stake in shares of Infinity Pharmaceuticals during the 3rd quarter valued at about $745,000. 54.12% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on INFI. UBS Group restated a “reduce” rating on shares of Infinity Pharmaceuticals in a research note on Monday, January 7th. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Wednesday, January 2nd. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Finally, B. Riley began coverage on shares of Infinity Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Infinity Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $2.83.

ILLEGAL ACTIVITY WARNING: “Infinity Pharmaceuticals (INFI) Issues Earnings Results” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://theolympiareport.com/2019/03/15/infinity-pharmaceuticals-infi-issues-earnings-results.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Story: Short Selling

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.